Sandip P. Patel, MD, speculates on promising research directions in early non–small cell lung cancer (NSCLC), including enlarged exploration of driver mutations and their implications for the standard treatment options, the dilemmas surrounding patients who do not achieve complete pathologic response after neoadjuvant therapy, and the earlier use of targeted and immunotherapies in the effort to improve survival rates.
Together, Dr Patel suggests, these lines of investigation form a map that represents the quickly evolving topography in the area of NSCLC therapeutics.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Early NSCLC: New Topographies in Non–Small Cell Lung Cancer Research - Medscape - Aug 11, 2022.